Modern-Day Cancer Therapy: A Case Study

It has broad variety of anti-tumor activity and forms the backbone of combination chemotherapy regimes presently

Some of traditional drugs may be effective in patients whose cancers have a specific molecular target, and not for other patients. To solve this problem of patient-specificity, pharmaceutical research have seen the expansion of individually tailored cancer treatment, which is an application of targeted therapy, and this is where biopharmaceuticals are. As an increasing part of the population is diagnosed with cancer and as these patients live longer, increasing care will be given to patients who have received these drugs. Moreover, in the case of cancer therapy, those drugs and especially with mABs are a promise of less side effects : recombinant DNA technology makes it possible to genetically engineer an antibody to reduce the risk of host immune response.

Many doctors, physicians, researchers and biotech companies--including the revolutionary Seattle Genetics research facility--are now turning to antibody-assisted cancer treatments and precisely targeted cures instead of treating cancer with a cocktail of chemicals and radiation that generate risky side effects and damage the healthy tissue that patients need to recover. Cancers are among the most frightening and difficult-to-treat illnesses. Ranked as the leading cause of death and disability, cancer is actually an umbrella term that covers many different diseases. Each person faces a unique disease because cancers interact with the body's existing cells, so each case has a

A team from the Brazilian university says the experimental drug binds with tumor cells and causes the loss of key molecules.

Abstract Cancer “Sucks” and many individuals today are dealing with it or know someone who has dealt with it. The late president Richard Nixon declared war on cancer in 1971 and we have been fighting the battle ever since (McCarthy, 2015, paras. 16). Since the declaration many possible cures were developed and chemotherapy is the one which seems to work on almost every cancer. However, this treatment has drawbacks that are either controversial or questionable as to what degree they help with defeating cancer.

It would attach itself to a cancer cell and aggressively aggravate the body to draw in the bodies’ defenses to all out assault that area. In theory, if you kept the patients immune system going, you could bombard the cancer and not have to worry about chemical side effects. Lots of treatments like chemotherapy weaken the immune system, so this would be an interesting alternative. One would first need to figure out a way to attach a “decoy” drug to the cancer cells and have it be one that the body would want to attack.

Cancer has presented itself as a constant treat for humanity all along its history and for most of it, a dark and grim perspective was the only outcome for the people afflicted by this condition. However with the arrival of the scientific method and the subsequent development of modern medicine during the XIX and XX centuries new ways of treating this condition were found. With innovations in surgery methods as the general anesthesia in 1846 by William Morton and the mastectomy procedure in 1880s (Halsted, 1894) medicine started an arms race against cancer. Later in the XX century, new tools in the form of chemical compounds were found to preferentially attack the tumor cells. During the post-war period and old weapon of war the nitrogen mustard,

Advances in science and medical technologies throughout the years have lead to a great number of discoveries over the years. Vaccines, antibodies, and many other pharmaceuticals that are produced have provided cures and treatments for ailments that plague society. However, despite all those advancements, cancer continues to be a condition that a prefect treatment eludes our grasp. Fortunately, scientist have worked diligently on new forms of therapy to battle cancer. One such chemotherapy is Kymriah.

Background: A main challenge in chemotherapy is the delivery of an effective dose of a given cytotoxic agent to the tumor site. Immunotoxins are protein-based drugs consist of a target-specific binding domain with a cytotoxic domain to eliminate target cells. Such compounds are potentially therapeutic against diseases such as cancer. The B-subunit of shiga toxin (STXB), which is nontoxic and possess low immunogenicity, accurately binds to the globotriaosylceramide (GB3/CD77), that is expressed in high amounts on a number of human tumors for example pancreatic, colon, and breast cancer cells. Therefore, this toxin can be applied to target GB3-positive human tumors. In this study, we evaluate a new antitumor candidate called DT-STXB chimeric

To date MSK has twenty-four facilities throughout New York and New Jersey providing a multitude of inpatient and outpatient services associated with the study, diagnosis and treatment of various forms of cancer. The Memorial hospital accommodates 471 beds, a 72,000-square-foot surgical center and state-of-the-art outpatient treatment center (Memorial Sloan Kettering Cancer Center, 2015c). MSK houses more than 35 core facilities with research being conducted in over 120 laboratories. Core facilities are dedicated to the development of scientific technology that aids in the study and treatment of cancer. Additionally Gerstner Sloan Kettering Graduate School of Biomedical Sciences and Weill Cornell Graduate School of

Bacteria accurately target tumors, actively enter tissue, simply recognized and controllably produce cytotoxicity. also, Several popular cures such as chemotherapy and radiation are poisonous for healthy tissue and not fully damage every cancer cells. Three main reasons for these difficulties are deficient tumor targeting, poor tissue invasion and insufficient toxicity to each cancer cells. These disadvantages limit qualified therapy and are linked with the rise in morbidity and mortality.

As the world continues to suffer from these devastating diseases, researchers continue to find alternative therapeutic ways of addressing cancer treatment. It is on this premise that various immunotherapeutic alternatives have emerged and currently garnering the greatest level of attention and already raising hope throughout the world in addressing the treatment of NSCLC. However, this can no longer be viewed as a discovery but a wave in the medicine world that began in the 20th century. Various researchers have found the importance of the role of immune systems in fighting the growth of tumor caused by cancer cells. A study by Huncharek (2000) stated that specific immune boosters are capable of eliminating preclinical cancers. In contrast, Jermal et al. (2011) found that immunotherapy is an effective approach for the treatment of tumors that have already turned into solid. Similarly, the researchers highlighted that immunotherapy can be an effective approach to the treatment of melanoma as well as renal cell cancers (Lasalvia-Prisco, 2008). However, Jemal et al. (2011) noted that immunotherapy cannot achieve much in cancer treatment due to limitation brought about by the emission of immunosuppressive cytokines and subsequent loss of antigen expressions. Recent development in research studies on the immunotherapy approach to cancer treatment continues to elicit mixed reactions among researchers of medicinal ecology (Jadad et al., 1996). However, recent development in

Cancer is one of the more prevalent diseases in our world today. It’s a horrifying diagnosis that affects not only the patient, but their families and loved ones as well. As nurses, we deal head on with this diagnoses on a daily basis. Holding a strong front becomes hard, when inside, you’re crumbling while looking at the sweet 4 year old girl, taking her last breath in the face of her leukemia with a smile on her face. Hopefully one day, we won’t have to endure the pain and heartbreak of losing patients to cancer. Hopefully one day, we’ll be able to look patients and their families in the eyes, and say ‘this is nothing to worry about – we have a cure’. (One can dream, even if it is an unrealistic dream). For now, however, there are numerous ways to help fight cancer in patients.

Cancer, since the beginning of history, has plagued humanity and claimed countless lives. For thousands of years, doctors could do little more than watch with horror as their patients succumbed to the often fatal condition. There is still no definite cure for cancer. However, while one might say that treatment is still in its infancy today, therapies have evolved dramatically over the last century. The innovation of chemotherapy marked a turning point in cancer treatment. Dr. Sidney Farber, a pediatric pathologist, is regarded as the father of modern chemotherapy due to his success in inducing remission in leukemia patients through the use of chemical agents. Through Dr. Farber’s innovation, chemotherapy strengthened the relationship

In the seminar given to us by Damien Samways, we were exposed to the research and discoveries linked to transmembrane transport mechanisms for selective drug delivery, specifically leading into selective permeabilization of cervical cancer cells. We learned that the beginning of the research was based mainly on the ATP and calcium in cells and how they could be used or manipulated for transport and permeabilization used to get drugs into cells and were faced with the question if this could have a therapeutic effect. The research was soon focused onto the P2x and P2y receptors of the cell, which are ion channels activated by ATP. Further research on the receptors determined that ATP could permeabilize cells and some channels within the cells transport therapeutic drugs using a process called selective silencing. With this information, the curiosity arose for the use of anticancer drugs with and intracellular target, although this process had known problems. The concerns included getting the drug across the plasma membrane of the cells and the fact that they only wanted the drug to get into cancer cells, not all cells. In the lab model, fluorescent cytotoxins were used to determine the uptake into the cells. A hypothesis was then made the ATP can permeabilize cells to some small fluorescent cytotoxins. Focus was then placed on the P2y receptors and the original idea of ATP, which can be used to increase the permeability of cancer cells and